Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunogenicity and safety of inactivated and mRNA COVID-19 vaccines in patients with systemic lupus erythematosus
Ho So, Tena Li, Vivien Kin Yi Chan, et al.
Therapeutic Advances in Musculoskeletal Disease (2022) Vol. 14
Open Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

Systemic lupus erythematosus in the light of the COVID-19 pandemic: infection, vaccination, and impact on disease management
Pankti Mehta, Armen Yuri Gasparyan, Olena Zimba, et al.
Clinical Rheumatology (2022) Vol. 41, Iss. 9, pp. 2893-2910
Open Access | Times Cited: 32
Effect of DMARDs on the immunogenicity of vaccines
Yannick van Sleen, Kornelis S. M. van der Geest, Anke Huckriede, et al.
Nature Reviews Rheumatology (2023) Vol. 19, Iss. 9, pp. 560-575
Closed Access | Times Cited: 18
Systemic lupus erythematosus following COVID-19 vaccination. A systematic review of case reports and case series
Nelson Luis Cahuapaza-Gutierrez
Lupus (2024) Vol. 33, Iss. 4, pp. 375-386
Closed Access | Times Cited: 6
Self‐Reported Delayed Adverse Events and Flare Following COVID‐19 Vaccination Among Patients With Autoimmune Rheumatic Disease (AIRD) in Malaysia: Results From the COVAD‐2 Study
Syahrul Sazliyana Shaharir, Azmawati Mohammed Nawi, Theepa Nesam Mariamutu, et al.
International Journal of Rheumatic Diseases (2025) Vol. 28, Iss. 1
Closed Access
Efficacy of mRNA and Inactivated Whole Virus Vaccines Against COVID-19 in Patients with Chronic Respiratory Diseases
Wang Chun Kwok, Sze Him Isaac Leung, Terence Chi Chun Tam, et al.
International Journal of COPD (2023) Vol. Volume 18, pp. 47-56
Open Access | Times Cited: 13
Immunogenicity and safety of BNT162b2 vaccination in adolescents with systemic lupus erythematosus
Nuntawan Piyaphanee, Sirirat Charuvanij, Sutheera Thepveera, et al.
Lupus (2024) Vol. 33, Iss. 5, pp. 450-461
Closed Access | Times Cited: 4
Impact of Immunomodulatory Therapy on COVID-19 Vaccine Response in Patients with Autoimmune Inflammatory Rheumatic Diseases
Ruth Xian Lynn Yap, Yi Wye Lai, Chang Wei, et al.
Vaccines (2024) Vol. 12, Iss. 3, pp. 274-274
Open Access | Times Cited: 4
COVID-19 vaccination in systemic lupus erythematosus: a systematic review of its effectiveness, immunogenicity, flares and acceptance
Shaun Ye Song Tan, Aaron Mingyang Yee, Jackie Jia Lin Sim, et al.
Lara D. Veeken (2022) Vol. 62, Iss. 5, pp. 1757-1772
Open Access | Times Cited: 21
Systemic Lupus Erythematosus and COVID-19
Μαρία Παππά, Alexandros Panagiotopoulos, Κonstantinos Thomas, et al.
Current Rheumatology Reports (2023) Vol. 25, Iss. 10, pp. 192-203
Open Access | Times Cited: 11
Efficacy, Immunogenicity, and Safety of COVID-19 Vaccines in Patients with Autoimmune Diseases: A Systematic Review and Meta-Analysis
Alvina Widhani, Anshari Saifuddin Hasibuan, Retia Rismawati, et al.
Vaccines (2023) Vol. 11, Iss. 9, pp. 1456-1456
Open Access | Times Cited: 10
Systemic sclerosis and COVID-19 vaccine safety: short-term insights from the global COVID-19 vaccination in autoimmune disease (COVAD) survey
R Naveen, Darpan R. Thakare, Masataka Kuwana, et al.
Rheumatology International (2023) Vol. 43, Iss. 7, pp. 1265-1275
Open Access | Times Cited: 7
Immunogenicity and Safety of mRNA Anti-SARS-CoV-2 Vaccines in Patients with Systemic Lupus Erythematosus
Ilaria Mormile, Francesca Della Casa, Angelica Petraroli, et al.
Vaccines (2022) Vol. 10, Iss. 8, pp. 1221-1221
Open Access | Times Cited: 8
Glucocorticoid use as a cause of non-cellular immune response to SARS-Cov2 Spike in patients with immune system diseases
Yves Renaudineau, L. Sailler, Florence Abravanel, et al.
Journal of Autoimmunity (2022) Vol. 133, pp. 102912-102912
Open Access | Times Cited: 8
Autoimmune rheumatic diseases and COVID-19 vaccination: a retrospective cross-sectional study from Astana
Kristina Rutskaya-Moroshan, Saule Abisheva, Madina Sarsenova, et al.
Reumatologia/Rheumatology (2024) Vol. 62, Iss. 1, pp. 26-34
Open Access | Times Cited: 1
COVID-19 vaccination and cerebral small vessel disease progression - A prospective cohort study
Bonaventure Ip, Sangqi Pan, Alan Yao, et al.
International Journal of Infectious Diseases (2024) Vol. 151, pp. 107324-107324
Closed Access | Times Cited: 1
Assessment of antibody levels to SARS-CoV-2 in patients with idiopathic inflammatory myopathies receiving treatment with intravenous immunoglobulin
Sangmee Bae, Emmanuelle Faure-Kumar, Kathie G. Ferbas, et al.
Rheumatology International (2023) Vol. 43, Iss. 9, pp. 1629-1636
Open Access | Times Cited: 2
Immunogenicity and Safety of Half-Dose Heterologous mRNA-1273 Booster Vaccination for Adults Primed with the CoronaVac® and ChAdOx1-S Vaccines for SARS-CoV-2
Nina Dwi Putri, Aqila Sakina Zhafira, Pratama Wicaksana, et al.
Vaccines (2024) Vol. 12, Iss. 4, pp. 344-344
Open Access
Humoral immunity and safety of respiratory virus vaccines in systemic lupus erythematosus population: a meta-analysis based on twenty-five observational studies
Xiaozheng Li, Yawei Li, Chengyang Huang, et al.
Annals of Medicine (2024) Vol. 56, Iss. 1
Open Access
Favourable humoral but reduced cellular immune response to COVID-19 mRNA BNT162b2 vaccine in patients with childhood-onset systemic lupus erythematosus
Esra Karabağ Yılmaz, Ayşe Ağbaş, Nur Canpolat, et al.
Lupus Science & Medicine (2024) Vol. 11, Iss. 2, pp. e001268-e001268
Open Access
Anti–severe acute respiratory syndrome coronavirus 2 spike receptor-binding domain antibody levels in patients with systemic lupus erythematosus based on vaccination status and related factors in Indonesia
Laniyati Hamijoyo, Patrick Philo, Daniel Setiawan Nathan, et al.
Clinical and Experimental Vaccine Research (2024) Vol. 13, Iss. 4, pp. 348-348
Open Access
COVID‐19 Vaccination in Patients With Systemic Lupus Erythematosus: Adverse Events and Rating Agreement of Flares Between Patients and Physicians
Punsita Tangkum, Nuntana Kasitanon, Wanitcha Gumtorntip, et al.
International Journal of Rheumatic Diseases (2024) Vol. 27, Iss. 12
Closed Access
Flares and Predicting Factors of Flares in Patients with Systemic Lupus Erythematosus Associated with Different Doses and Types of COVID-19 Vaccines
Worawit Louthrenoo, Punsita Tangkum, Nuntana Kasitanon, et al.
Vaccines (2024) Vol. 12, Iss. 12, pp. 1399-1399
Open Access
Higher antibody responses after mRNA-based vaccine compared to inactivated vaccine against SARS-CoV-2 in Behcet’s syndrome
Ayşe Özdede, Okan Kadir Nohut, Zeynep Atlı, et al.
Rheumatology International (2022) Vol. 42, Iss. 10, pp. 1741-1750
Open Access | Times Cited: 3
Impaired neutralizing antibodies and preserved cellular immunogenicity against SARS-CoV-2 in systemic autoimmune rheumatic diseases
Porntip Intapiboon, Parichat Uae-areewongsa, Jomkwan Ongarj, et al.
npj Vaccines (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 3
Glucocorticoids selectively affect the memory T cell response to SARS-Cov2 spike in vaccinated and post-infected patients with systemic lupus erythematosus
Yves Renaudineau, Chloé Bost, Florence Abravanel, et al.
Journal of Translational Autoimmunity (2023) Vol. 6, pp. 100200-100200
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top